moneyheap
VKTX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Viking Therapeutics, Inc. (VKTX) stock moving?
Viking reported Q3 2026 results on Oct 28 with a loss per share of $(1.55), well above the $(1.07) estimate, and a net loss of $183.2M. The company offset this with a $960M quarter-end cash balance, positive top-line maintenance data for VK2735, the start of Part 2 of that study, and the initiation of the SUNRISE oral Phase 3 program alongside the ongoing VANQUISH subcutaneous Phase 3. Shares jumped 5.9% on Oct 29 on 6.75M volume, the heaviest day in the window, and then traded mostly between $25 and $28. Canaccord kept its Buy rating and lifted its target to $118 on Oct 31, roughly four times the Nov 10 close of $28.66. On Nov 9 the stock rose 8.0% to $28.99 on 4.1M volume, and on Nov 10 it touched a 30-day high of $30.10 before closing at $28.66, below the session VWAP of $29.08. That late-session fade is a caution. The stock is up about 17% from its Oct 23 close of $24.40. Two items weigh on the outlook: the Sep 23 equity offering priced at $35.00 per share, now above the share price, and the wider loss. Pipeline readouts remain ahead, so the outcome is not yet settled.
News behind the analysis
- Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026Viking will present two posters with data from its clinical programs at the ObesityWeek 2026 conference.
- Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118Canaccord Genuity kept its Buy rating on Viking and raised its price target to $118.
- Viking Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Trial ProgressViking reported a Q3 2026 net loss of $183.2M and confirmed enrollment completion for its VK2735 injectable trials.
- Viking Therapeutics Stock Jumps: What's Going On?Shares rose after Q3 results paired a wider-than-expected loss with positive study data and a $960 million cash balance.
- Viking Therapeutics Reports Third Quarter 2026 Financial ResultsViking reported Q3 and nine-month 2026 results, initiated the SUNRISE oral Phase 3 program and ended the quarter with $960M in cash.
- Viking Therapeutics Q3 EPS $(1.55) Misses $(1.07) EstimateViking's Q3 2026 loss per share of $(1.55) was wider than the $(1.07) analyst estimate.
About Viking Therapeutics, Inc
Viking Therapeutics is a San Diego biotech company in the clinical stage, meaning its drugs are still being tested in trials. It is developing treatments for metabolic and endocrine disorders, and its lead drug is VK2735, an obesity treatment in both injectable and oral pill forms. The injectable is in Phase 3 (VANQUISH) trials, and Phase 3 (SUNRISE) trials of the pill began in 2026.
How it makes money
Viking has no approved products and no meaningful revenue. It pays for research by raising money from investors, most recently through an upsized offering of about $500 million in stock and convertible notes in September 2026. Research spending is heavy: the net loss was about $128 million in Q2 2026, and the company held about $502 million in cash and short-term investments at mid-2026, before that raise. Any future income would come from selling drugs if they are approved, or from partnership or licensing deals.
What usually moves VKTX
- VK2735 Phase 3 trial results (VANQUISH and SUNRISE)
- Competition in the obesity drug market (GLP-1 drugs)
- Regulatory decisions and trial timelines
- Share sales and convertible notes that dilute existing shareholders
- Takeover or partnership speculation